Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development
Abra G Brisbin, Yan W Asmann, Honglin Song, Ya-Yu Tsai, Jeremiah A Aakre, Ping Yang, Robert B Jenkins, Paul Pharoah, Fredrick Schumacher, David V Conti, David J Duggan, Mark Jenkins, John Hopper, Steven Gallinger, Polly Newcomb, Graham Casey, Thomas A Sellers, Brooke L Fridley
BMC Medical Genetics | BIOMED CENTRAL LTD | Published : 2011
Awarded by National Cancer Institute, National Institutes of Health
We thank Margaret Wrensch and Paul Decker for access to the association results from the glioma case-control study; Ellen L. Goode, Joellen M. Schildkraut, Steven Narod, and Rebecca Sutphen for contribution of the US ovarian case-control association results; Jonathan Tyrer, Simon Gayther, and Susan Ramus for contribution of the UK ovarian case-control association results; and the Mayo Genotyping Shared Resource for genotyping the never-smokers lung cancer study. We also thank the Cancer Genetic Markers of Susceptibility (CGEMS) project for providing results for the breast, prostate, pancreatic and lung cancer for the 8q24 region via dbGaP. The research was supported by R01 CA114343 (Sellers), P50 CA108961 (Mayo Clinic Brain Tumor SPORE), RC1 NS068222 (Jenkins), R01 CA80127 (Yang), R01 CA84354 (Yang), R21 CA140879 (Fridley), R21 GM86689 (Fridley), the Minnesota Partnership for Biotechnology and Medical Genomics (Fridley), and the Mayo Foundation. Colon cancer data were provided by the Australian Colorectal Cancer Family Registry (U01 CA097735), the Ontario Registry for Studies of Familial Colorectal Cancer (U01 CA074783), and the Seattle Colorectal Cancer Family Registry (U01 CA074794). This work was supported by the National Cancer Institute, National Institutes of Health under RFA # CA-95-011 and through cooperative agreements with members of the Colon Cancer Family Registry and PIs. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the CFRs, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the CFR. The funding bodies did not influence the study design, the collection, analysis, or interpretation of data, the writing of the manuscript, or the decision to submit the manuscript for publication.